{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:00:20Z","timestamp":1772164820665,"version":"3.50.1"},"reference-count":52,"publisher":"American Association for Cancer Research (AACR)","issue":"12","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R37CA261987\/R00CA194318"],"award-info":[{"award-number":["R37CA261987\/R00CA194318"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1R01CA288651"],"award-info":[{"award-number":["1R01CA288651"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["I01 BX006020"],"award-info":[{"award-number":["I01 BX006020"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA046934"],"award-info":[{"award-number":["P30CA046934"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["2201538"],"award-info":[{"award-number":["2201538"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sandy Rollman Ovarian Cancer Foundation"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>PARP inhibitors (PARPi) have reshaped the clinical management paradigm of multiple cancers, but none more than homologous recombination\u2013deficient high-grade serous carcinoma (HGSC) of tubo-ovarian origin. In patients with HGSC that harbor BRCA1\/2-mutations, PARPi maintenance therapy after first-line chemotherapy has resulted in significantly prolonged progression-free and overall survival. However, PARPi resistance is a major clinical challenge, and subsequent therapeutic options for patients with resistant disease remain limited. Whereas mechanisms of PARPi therapy have been described, there have been few clinical studies to translate these strategies into overcoming resistance. Elevated WNT signaling and T-cell factor (TCF) transcriptional activity contribute to PARPi resistance; however, directly targeting WNT signaling is challenging due to on-target adverse events. We tested an indirect WNT inhibitor, a dual CDC-like kinase and dual-specificity tyrosine phosphorylation\u2013regulated kinase inhibitor, SM08502 (cirtuvivint), in combination with PARPi in multiple resistant HGSC models. We determined TCF transcriptional activity and differential gene expression with splicing analysis and used multispectral IHC to interrogate the tumor microenvironment. In PARPi-resistant models, SM08502 inhibits WNT\/TCF transcriptional activity, reduces cell viability, and induces DNA damage. In addition, using multiple immune-compromised and immune-intact in vivo models of PARPi-resistant disease, SM08502, in combination with olaparib, significantly reduces disease progression, remodels the tumor immune microenvironment, and extends survival. Specifically, tumors treated with the SM08502\/olaparib combination exhibit reduced immune-suppressive PD-1 and PD-L1 expression. This study provides strong preclinical evidence that SM08502, in combination with PARPi, may be an effective strategy to overcome PARPi resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>PARPi resistance is a major clinical challenge. Overcoming PARPi resistance will provide patients with therapeutic options. The study shows, in the context of resistant disease, the potential of targeting CDC-like kinase\/dual-specificity tyrosine phosphorylation\u2013regulated kinase alone and in combination with PARP inhibitors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0267","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T07:01:46Z","timestamp":1764831706000},"page":"2112-2126","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SM08502-Mediated \u03b2-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6608-2585","authenticated-orcid":false,"given":"Bradley R.","family":"Corr","sequence":"first","affiliation":[{"name":"1Division of Gynecologic Oncology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0237-7453","authenticated-orcid":false,"given":"Elizabeth R.","family":"Woodruff","sequence":"additional","affiliation":[{"name":"2Division of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6666-5406","authenticated-orcid":false,"given":"Tomomi M.","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"2Division of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8380-7157","authenticated-orcid":false,"given":"Kimberly R.","family":"Jordan","sequence":"additional","affiliation":[{"name":"3Department of Immunology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3861-8602","authenticated-orcid":false,"given":"Thomas","family":"Danhorn","sequence":"additional","affiliation":[{"name":"4University of Colorado Cancer Center, Department of Biomedical Informatics, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2508-7282","authenticated-orcid":false,"given":"Carine","family":"Bossard","sequence":"additional","affiliation":[{"name":"5Biosplice, Inc., San Diego, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4425-2536","authenticated-orcid":false,"given":"Lily L.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"6Department of Molecular Cellular and Developmental Biology, BioFrontiers Institute, University of Colorado Boulder, Boulder, Colorado."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5392-937X","authenticated-orcid":false,"given":"Edward B.","family":"Chuong","sequence":"additional","affiliation":[{"name":"6Department of Molecular Cellular and Developmental Biology, BioFrontiers Institute, University of Colorado Boulder, Boulder, Colorado."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3479-8053","authenticated-orcid":false,"given":"Lars","family":"Wick","sequence":"additional","affiliation":[{"name":"7Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, Colorado."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8709-439X","authenticated-orcid":false,"given":"Alexandra","family":"Young","sequence":"additional","affiliation":[{"name":"8Caris Life Sciences, Phoenix, Arizona."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4551-6719","authenticated-orcid":false,"given":"Shinya","family":"Kusumoto","sequence":"additional","affiliation":[{"name":"9Department of OB\/GYN, UCLA David Geffen School of Medicine, Los Angeles, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5119-8721","authenticated-orcid":false,"given":"Sandra","family":"Orsulic","sequence":"additional","affiliation":[{"name":"9Department of OB\/GYN, UCLA David Geffen School of Medicine, Los Angeles, California."},{"name":"10Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California."},{"name":"11Department of Veterans Affairs, Greater Los Angeles Healthcare System, Los Angeles, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9315-2414","authenticated-orcid":false,"given":"Lisa","family":"Barroilhet","sequence":"additional","affiliation":[{"name":"12Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Wisconsin, Madison, Wisconsin."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5809-5271","authenticated-orcid":false,"given":"Benjamin G.","family":"Bitler","sequence":"additional","affiliation":[{"name":"2Division of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"2025120504514699200_bib1","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","article-title":"Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer","volume":"5","author":"Konstantinopoulos","year":"2015","journal-title":"Cancer Discov"},{"key":"2025120504514699200_bib2","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"key":"2025120504514699200_bib3","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","article-title":"Understanding and overcoming resistance to PARP inhibitors in cancer therapy","volume":"18","author":"Dias","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2025120504514699200_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1541-7786.MCR-22-0102","article-title":"ATF6-mediated signaling contributes to PARP inhibitor resistance in ovarian cancer","volume":"21","author":"McMellen","year":"2023","journal-title":"Mol Cancer Res"},{"key":"2025120504514699200_bib5","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13148-019-0758-2","article-title":"Histone methyltransferases EHMT1 and EHMT2 (GLP\/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma","volume":"11","author":"Watson","year":"2019","journal-title":"Clin Epigenetics"},{"key":"2025120504514699200_bib6","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1002\/mc.23064","article-title":"Activation of Wnt signaling promotes olaparib resistant ovarian cancer","volume":"58","author":"Yamamoto","year":"2019","journal-title":"Mol Carcinog"},{"key":"2025120504514699200_bib7","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrd4233","article-title":"Can we safely target the WNT pathway?","volume":"13","author":"Kahn","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"2025120504514699200_bib8","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.cell.2006.10.018","article-title":"Wnt\/beta-catenin signaling in development and disease","volume":"127","author":"Clevers","year":"2006","journal-title":"Cell"},{"key":"2025120504514699200_bib9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41392-021-00762-6","article-title":"Wnt\/\u03b2-catenin signalling: function, biological mechanisms, and therapeutic opportunities","volume":"7","author":"Liu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"2025120504514699200_bib10","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nri2360","article-title":"WNT signalling in the immune system: WNT is spreading its wings","volume":"8","author":"Staal","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"2025120504514699200_bib11","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.canlet.2019.09.009","article-title":"The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models","volume":"473","author":"Tam","year":"2020","journal-title":"Cancer Lett"},{"issue":"Suppl 1","key":"2025120504514699200_bib12","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1182\/blood-2021-151305","article-title":"The pan-Clk\/Dyrk inhibitor cirtuvivint (SM08502) exposes mechanistic underpinnings of alternative splicing as a therapeutic vulnerability in heme malignancies","volume":"138","author":"Bossard","year":"2021","journal-title":"Blood"},{"issue":"Suppl 7","key":"2025120504514699200_bib13","doi-asserted-by":"crossref","first-page":"S742","DOI":"10.1016\/j.annonc.2022.07.580","article-title":"451O Preliminary evidence of clinical activity from phase I and Ib trials of the CLK\/DYRK inhibitor cirtuvivint (CIRT) in subjects with advanced solid tumors","volume":"33","author":"Scott","year":"2022","journal-title":"Ann Oncol"},{"key":"2025120504514699200_bib14","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.1158\/1078-0432.CCR-17-3697","article-title":"Dual Src and MEK inhibition decreases ovarian cancer growth and targets tumor initiating stem-like cells","volume":"24","author":"Simpkins","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2025120504514699200_bib15","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1158\/1541-7786.MCR-06-0234","article-title":"Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation","volume":"5","author":"DelloRusso","year":"2007","journal-title":"Mol Cancer Res"},{"key":"2025120504514699200_bib16","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nm.3799","article-title":"Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers","volume":"21","author":"Bitler","year":"2015","journal-title":"Nat Med"},{"key":"2025120504514699200_bib17","doi-asserted-by":"crossref","first-page":"6184","DOI":"10.1158\/0008-5472.CAN-11-1341","article-title":"Wnt5a suppresses epithelial ovarian cancer by promoting cellular senescence","volume":"71","author":"Bitler","year":"2011","journal-title":"Cancer Res"},{"key":"2025120504514699200_bib18","doi-asserted-by":"crossref","first-page":"19950","DOI":"10.1074\/jbc.RA119.009615","article-title":"Wnt family member 4 (WNT4) and WNT3A activate cell-autonomous Wnt signaling independent of porcupine O-acyltransferase or Wnt secretion","volume":"294","author":"Rao","year":"2019","journal-title":"J Biol Chem"},{"key":"2025120504514699200_bib19","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res"},{"key":"2025120504514699200_bib20","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1083\/jcb.133.5.1123","article-title":"Activities of the Wnt-1 class of secreted signaling factors are antagonized by the Wnt-5A class and by a dominant negative cadherin in early Xenopus development","volume":"133","author":"Torres","year":"1996","journal-title":"J Cell Biol"},{"key":"2025120504514699200_bib21","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat Methods"},{"key":"2025120504514699200_bib22","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1158\/1541-7786.MCR-19-1057","article-title":"Targeting fatty acid oxidation to promote anoikis and inhibit ovarian cancer progression","volume":"18","author":"Sawyer","year":"2020","journal-title":"Mol Cancer Res"},{"key":"2025120504514699200_bib23","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1158\/1541-7786.MCR-24-0067","article-title":"EHMT1\/2 inhibition promotes regression of therapy-resistant ovarian cancer tumors in a CD8 T-cell-dependent manner","volume":"22","author":"Nguyen","year":"2024","journal-title":"Mol Cancer Res"},{"key":"2025120504514699200_bib24","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41587-020-0439-x","article-title":"The nf-core framework for community-curated bioinformatics pipelines","volume":"38","author":"Ewels","year":"2020","journal-title":"Nat Biotechnol"},{"key":"2025120504514699200_bib25","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"Limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"2025120504514699200_bib26","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"2018","journal-title":"J R Stat Soc"},{"key":"2025120504514699200_bib27","doi-asserted-by":"crossref","first-page":"E5593","DOI":"10.1073\/pnas.1419161111","article-title":"rMATS: robust and flexible detection of differential alternative splicing from replicate RNA-Seq data","volume":"111","author":"Shen","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025120504514699200_bib28","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1101\/gr.133744.111","article-title":"Detecting differential usage of exons from RNA-seq data","volume":"22","author":"Anders","year":"2012","journal-title":"Genome Res"},{"key":"2025120504514699200_bib29","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"OMICS"},{"key":"2025120504514699200_bib30","doi-asserted-by":"crossref","first-page":"6362","DOI":"10.1158\/1078-0432.CCR-20-1762","article-title":"The capacity of the ovarian cancer tumor microenvironment to integrate inflammation signaling conveys a shorter disease-free interval","volume":"26","author":"Jordan","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2025120504514699200_bib31","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0960-9822(03)00240-9","article-title":"Zebrafish prickle, a modulator of noncanonical Wnt\/Fz signaling, regulates gastrulation movements","volume":"13","author":"Veeman","year":"2003","journal-title":"Curr Biol"},{"key":"2025120504514699200_bib32","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1158\/0008-5472.CAN-14-3763","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method\u2013letter","volume":"75","author":"Ashton","year":"2015","journal-title":"Cancer Res"},{"key":"2025120504514699200_bib33","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1158\/1535-7163.MCT-21-0682","article-title":"Targeting DUSP activity as a treatment for high grade serous ovarian carcinoma","volume":"21","author":"Sanders","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"2025120504514699200_bib34","doi-asserted-by":"crossref","first-page":"e0116929","DOI":"10.1371\/journal.pone.0116929","article-title":"Inhibitors of CLK protein kinases suppress cell growth and induce apoptosis by modulating pre-mRNA splicing","volume":"10","author":"Araki","year":"2015","journal-title":"PLoS One"},{"key":"2025120504514699200_bib35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1083\/jcb.201107093","article-title":"Stress-responsive maturation of Clk1\/4 pre-mRNAs promotes phosphorylation of SR splicing factor","volume":"195","author":"Ninomiya","year":"2011","journal-title":"J Cell Biol"},{"key":"2025120504514699200_bib36","doi-asserted-by":"crossref","first-page":"10553","DOI":"10.1038\/ncomms10553","article-title":"Inactivation of nuclear GSK3\u03b2 by Ser(389) phosphorylation promotes lymphocyte fitness during DNA double-strand break response","volume":"7","author":"Thornton","year":"2016","journal-title":"Nat Commun"},{"key":"2025120504514699200_bib37","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.ymthe.2021.11.010","article-title":"Impacts and mechanisms of alternative mRNA splicing in cancer metabolism, immune response, and therapeutics","volume":"30","author":"Peng","year":"2022","journal-title":"Mol Ther"},{"key":"2025120504514699200_bib38","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1158\/1078-0432.CCR-24-1594","article-title":"Chemotherapy drives tertiary lymphoid structures that correlate with ICI-responsive TCF1+CD8+ T cells in metastatic ovarian cancer","volume":"31","author":"Lanickova","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2025120504514699200_bib39","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1158\/2326-6066.CIR-20-0968","article-title":"Chemotherapy induces tumor-associated macrophages that aid adaptive immune responses in ovarian cancer","volume":"9","author":"Heath","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"2025120504514699200_bib40","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.cmet.2019.02.016","article-title":"Membrane cholesterol efflux drives tumor-associated macrophage reprogramming and tumor progression","volume":"29","author":"Goossens","year":"2019","journal-title":"Cell Metab"},{"key":"2025120504514699200_bib41","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/s41416-023-02436-2","article-title":"A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours","volume":"130","author":"Burris","year":"2024","journal-title":"Br J Cancer"},{"key":"2025120504514699200_bib42","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1158\/2767-9764.CRC-24-0111","article-title":"BRCA status dictates Wnt responsiveness in epithelial ovarian cancer","volume":"4","author":"Chehade","year":"2024","journal-title":"Cancer Res Commun"},{"key":"2025120504514699200_bib43","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1038\/s41388-025-03561-3","article-title":"LEF1 confers resistance to DNA-damaging chemotherapies through upregulation of PARP1 and NUMA1 in ovarian cancer","volume":"44","author":"Huang","year":"2025","journal-title":"Oncogene"},{"key":"2025120504514699200_bib44","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/j.1460-2075.1996.tb00357.x","article-title":"The Clk\/Sty protein kinase phosphorylates SR splicing factors and regulates their intranuclear distribution","volume":"15","author":"Colwill","year":"1996","journal-title":"EMBO J"},{"key":"2025120504514699200_bib45","doi-asserted-by":"crossref","first-page":"24246","DOI":"10.1074\/jbc.M314298200","article-title":"Manipulation of alternative splicing by a newly developed inhibitor of Clks","volume":"279","author":"Muraki","year":"2004","journal-title":"J Biol Chem"},{"key":"2025120504514699200_bib46","doi-asserted-by":"crossref","first-page":"113307","DOI":"10.1016\/j.celrep.2023.113307","article-title":"Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma","volume":"42","author":"Xu","year":"2023","journal-title":"Cell Rep"},{"key":"2025120504514699200_bib47","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s10020-024-00849-0","article-title":"Downregulation of HNRNPA1 induced neoantigen generation via regulating alternative splicing","volume":"30","author":"Sun","year":"2024","journal-title":"Mol Med"},{"key":"2025120504514699200_bib48","doi-asserted-by":"crossref","first-page":"6118","DOI":"10.1158\/0008-5472.CAN-16-1272","article-title":"CRISPR\/Cas9-mediated Trp53 and Brca2 knockout to generate improved murine models of ovarian high-grade serous carcinoma","volume":"76","author":"Walton","year":"2016","journal-title":"Cancer Res"},{"key":"2025120504514699200_bib49","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1182\/blood-2013-02-481507","article-title":"NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML","volume":"123","author":"Adamia","year":"2014","journal-title":"Blood"},{"key":"2025120504514699200_bib50","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1158\/1078-0432.CCR-13-0956","article-title":"A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets","volume":"20","author":"Adamia","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2025120504514699200_bib51","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ygyno.2022.11.027","article-title":"AML and MDS associated with PARP inhibitor treatment of ovarian cancer","volume":"171","author":"Armstrong","year":"2023","journal-title":"Gynecol Oncol"},{"key":"2025120504514699200_bib52","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.ygyno.2021.03.011","article-title":"Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: a meta-analysis of randomized trials","volume":"161","author":"Nitecki","year":"2021","journal-title":"Gynecol Oncol"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/12\/2112\/3708596\/crc-25-0267.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/12\/2112\/3708596\/crc-25-0267.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T09:52:03Z","timestamp":1764928323000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/5\/12\/2112\/770340\/SM08502-Mediated-Catenin-Repression-Synergizes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":52,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0267","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.30783928","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30783949","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30800191","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30800197","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30800194","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30800212","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30800200","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30800203","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30783940","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30800209","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30783961","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30800206","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30783955","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30783943","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30783931","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30783964","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30783952","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30783937","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30783958","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30783946","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30783934","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30783967","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8183548","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]}}}